Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry

Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading to improved potency and durability in vivo versus comparator siRNA... | April 20, 2023

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Paul Bolno ,Chandra Vargeese ,Kate Rausch ,Wave Life Sciences Nasdaq ,Wave Life Sciences Fourth Quarter ,Exchange Commission ,Nasdaq ,Nucleic Acids Research ,Wave Life Sciences ,Wave Life Sciences Ltd ,Life Sciences ,Nucleic Acids ,Chief Technology Officer ,Platform Discovery Sciences ,Wave Life ,Chief Executive Officer ,Life Sciences Fourth Quarter ,Full Year ,Private Securities Litigation Reform Act ,Annual Report ,Wave Life Sciences Ltd Stock Exchange ,News ,Information ,Press Release ,Published ,Reclinical ,Data ,Emonstrate ,Unprecedented ,Go2 ,Loading ,Following ,Administration ,F ,Single ,Subcutaneous ,Dirna ,Reading ,O ,Mproved ,Potency ,End ,Durability ,N ,Ivo ,Versus ,Omparator Wve Sg9999014716 ,